BioNote

BioNote EBITDA per Employee

EBITDA per Employee of BioNote (377740.KS) as of Oct 18, 2026.

EBITDA per Employee

-KRW

Last updated:

EBITDA per Employee of BioNote is 2026 - KRW. EBITDA per Employee of BioNote was 2025 - KRW. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNote Stock analysis

What does BioNote do? BioNote Inc., headquartered in Hwaseong, South Korea, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures rapid diagnostic kits for humans and animals, including immunochemical and fluorescence-based diagnostic products. It also produces raw materials such as antigens, antibodies, and enzymes, along with semi-finished products for diagnostic use. Listed on December 22, 2022, BioNote focuses on veterinary and human diagnostic solutions. BioNote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNote stock

On Eulerpool you can find the complete historical development of EBITDA per Employee BioNote since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's BioNote historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — BioNote

All Key Metrics — BioNote